The following complimentary webcasts are scheduled. Please register to participate.
Please be aware that webinars are hosted through GoToWebinar. If you are not already set up to view webinars through this service, please allow 5 minutes before the start to establish access.
Register for upcoming webinars here:
Date: September 17th, 2014
Time: 16:00-16:40 GMT (London time)
The clinical applications of Next-Generation Sequencing (NGS) technologies are continuing to advance. Sanger sequencing is still generally considered the gold standard but this comes with low throughput and high cost (American College of Medical Genetics and Genomics, 2013). However advances in this Next Generation Sequencing are reducing the cost of sequencing, whilst facilitating new mechanisms for disease prediction.
Next Generation sequencing is becoming an appealing option with much higher throughput and potential to change the face of genetic medicine (American College of Medical Genetics and Genomics, 2013). However care must be taken to ensure high levels of control are maintained, this can be achieved through validation and reporting controls where specific NGS requirements are expected, in addition to those mandated by clinical accreditation and certification programmes.
Here we present the clinical application of next generation sequencing and implication of the latest NY State Guidelines.
Jonathan Frampton, PhD
Horizon Diagnostics, a business unit of Horizon Discovery Group plc is proud to support clinical laboratories with the provision of reference materials for research use; applications include the validation of equipment and consumables offline from patient testing. HDx™ Reference Standards are manufactured within a Quality Management System which complies with the requirements of ISO 9001:2008 and ISO 13485:2003.
Paragraph explaining benefits of Biocair×